The initiation of the placebo-controlled, dose-finding trial follows clearance from the US Food and Drug Administration (FDA) of the company’s investigational new drug (IND) application for HTX-011. HTX-011,
The new facility will manufacture packaging components for insulin injector cartridges and other high-value packaging components for injectable drugs. The 95,000ft² facility will be built at a 44-acre
The deal will see the two parties jointly work to develop new drugs to treat serious back-of-the-eye diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), geographic
Harbin Gloria Pharmaceuticals (Gloria) will design and conduct the trial under the terms of its exclusive license, development, commercialization and supply agreement with Sucampo for Amitiza in China.
The new facility, located near the company’s existing Suzhou site, will help increase production capacity to meet growing demand for Pfizer Consumer Healthcare’s brands in China and the
NTRA-9620 is intended to improve post-resection bowel adaptation as well as patient outcomes, which includes reducing reliance on parenteral nutrition support and increasing enteral nutrition intake. The company
The Phase III trial is planned to be conducted in collaboration with the Gynecologic Oncology Group (GOG) Foundation and will be led by principal investigator from University of
As part of the deal, KODE would secure up to $31m in development and sales milestones, plus royalties on net sales, while Agalimmune will have exclusive rights to
Reslizumab is the company’s investigational humanized monoclonal antibody (mAb), which targets interleukin-5 (IL-5), and is being reviewed as a potential treatment for patients with eosinophilic asthma, despite an
Olipudase alfa is being evaluated to treat nonneurological manifestations of ASMD, also known as Niemann-Pick disease type B, as opposed to type A, which is characterized by neurological
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.